ENDRA Life Sciences Inc.
NDRA
$3.50
-$0.16-4.37%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.26% | -14.39% | 25.83% | 21.79% | 25.41% |
| Total Depreciation and Amortization | -24.58% | -25.10% | -21.60% | -12.11% | 2.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 113.69% | 224.92% | 73.86% | 8.14% | 20.97% |
| Change in Net Operating Assets | 105.35% | 114.52% | -1,278.42% | -248.66% | -198.14% |
| Cash from Operations | 28.71% | 22.50% | 22.97% | 18.99% | 24.56% |
| Capital Expenditure | 81.42% | 52.80% | 65.09% | 71.55% | 75.84% |
| Sale of Property, Plant, and Equipment | -100.00% | -65.22% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 70.70% | 48.18% | 83.99% | 86.96% | 84.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | 7.21% | 20.86% | 45.75% | 103.83% | -7.48% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 546.27% | 546.27% | 38,227.36% | 4,949.25% | -- |
| Cash from Financing | -6.28% | 3.87% | 62.16% | 123.81% | 5.85% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 176.21% | 119.25% | 130.13% | 124.48% | 74.42% |